Demographic features of children who received anthracycline for their chemotherapy
| Total number of patients | n=110 (%) |
|---|---|
| Age (mean±SD) | 74±44 months |
| Males | 75 (68) |
| Body surface area (BSA)* | 0.84±0.32 |
| Type of malignancy | |
| Haematological malignancies | |
| ALL | 70 (64) |
| AML | 12 (11) |
| Non-haematological malignancies | |
| Hodgkin+non-Hodgkin | 19 (17) |
| Miscellaneous (Ewing sarcoma=4; Wilms tumour=5) | 9 (8) |
| Type of anthracycline | |
| Doxorubicin | 59 (53) |
| Combine doxorubicin and daunorubicin | 35 (32) |
| Daunorubicin | 16 (15) |
| Cumulative anthracycline dose (mg/m2) | |
| <100 | 40 (36) |
| 100–300 | 55 (50) |
| >300 | 15 (14) |
| Received radiation | 24 (22) |
| Discharge disposition | |
| Died | 7 (6) |
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia.